[
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $110.87 as of June 30th. GILD’s trailing and forward P/E were 23.29 and 14.01 respectively according to Yahoo Finance. Gilead Sciences (GILD) is a leading […]",
    "url": "https://finnhub.io/api/news?id=e82d17f57cb4616543ac16b65f40a1df66843ccfe46f432e00e08965843beec6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752171442,
      "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
      "id": 135866771,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $110.87 as of June 30th. GILD’s trailing and forward P/E were 23.29 and 14.01 respectively according to Yahoo Finance. Gilead Sciences (GILD) is a leading […]",
      "url": "https://finnhub.io/api/news?id=e82d17f57cb4616543ac16b65f40a1df66843ccfe46f432e00e08965843beec6"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a7feaee23a901489d45ea302f52084a39438aac3cc3d7dee85083222cb12b433",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752165360,
      "headline": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "id": 135950922,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a7feaee23a901489d45ea302f52084a39438aac3cc3d7dee85083222cb12b433"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=bfa1c267071d94c186b35b7d1abe49e97981f199e893f66be9d6469ff40aef7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752155402,
      "headline": "Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock",
      "id": 135856175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=bfa1c267071d94c186b35b7d1abe49e97981f199e893f66be9d6469ff40aef7e"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating",
    "summary": "Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock with an “Overweight” rating and a price objective of $70, down from $79. The research firm mentioned that the company is developing oral small-molecule approaches to […]",
    "url": "https://finnhub.io/api/news?id=a56fe430bc8e03db1399069b86a7e61aeb8fada838a752fd54c5f7cb5c2f4d38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752122385,
      "headline": "Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating",
      "id": 135844813,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock with an “Overweight” rating and a price objective of $70, down from $79. The research firm mentioned that the company is developing oral small-molecule approaches to […]",
      "url": "https://finnhub.io/api/news?id=a56fe430bc8e03db1399069b86a7e61aeb8fada838a752fd54c5f7cb5c2f4d38"
    }
  }
]